Evidence map›Paper›PMID 41889647›Full record

ArticleFrontiers in microbiology2026

Wild-type MIC distribution and evaluation of epidemiological cut-offs of second-line TB-drugs in susceptible and MDR-TB clinical isolates from Chennai, India.

Azger Dusthackeer, Mahizhaveni Balasubramanian, Sam Ebenezer Rajadas, Christy Rosaline Nirmal, Padmasini Elango, Kannan Thiruvengadam, Shainaba A Saadhali, Sivakumar Shanmugam

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Azger DusthackeerDepartment of Bacteriology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Mahizhaveni BalasubramanianDepartment of Bacteriology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Sam Ebenezer RajadasDepartment of Bacteriology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Christy Rosaline NirmalDepartment of Bacteriology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Padmasini ElangoDepartment of Bacteriology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Kannan ThiruvengadamDepartment of Statistics, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Shainaba A SaadhaliDepartment of Bacteriology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Sivakumar ShanmugamDepartment of Bacteriology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The rise of drug-resistant tuberculosis poses a significant challenge in patient management. Epidemiological cut-off values define drug resistance in Methods: The Broth microdilution-based Microscopic Observation Drug Susceptibility assay was employed to determine the minimum inhibitory concentration of the drugs against well-characterized wild-type and drug-resistant clinical Results and discussion: Deviations from the World Health Organization-recommended epidemiological cut-off values were observed, with lower thresholds for delamanid and levofloxacin and higher concentrations for clofazimine and bedaquiline. These shifts indicate region-specific susceptibility patterns in

Indexed as

drug resistanceepidemiological cut-off valuesminimum inhibitory concentration (MIC)Mycobacterium tuberculosispharmacodynamicssecond-line anti-TB drugs

Identifiers

PMID41889647
PMCPMC13013479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.